Observing viral biomarkers and microRNAs in oropharyngeal tumors and occult cancers related to HPV

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the presence and expression of HPV-DNA, specific microRNAs, and mutational profiles in patients with squamous cell carcinoma of the oropharynx and occult tumors. By analyzing tissue and biological fluids, the study seeks to determine the prognostic and diagnostic value of these biomarkers. Additionally, it aims to enhance the sensitivity and specificity of existing radiological methods like PET-CT and MRI for monitoring disease progression. The collected samples will also be used to create organoids and Patient Derived Xenografts (PDX) to explore potential new molecular drugs for overcoming resistance to treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Squamous cell carcinomas of the oropharynx and occult neoplasms with lymph node metastases laterocervical cytologically positive for squamous cell carcinoma treated with TORS or RT or RT/CT
* Age \> 18 years
* ECOG performance status \<\_ 2
* Ability to follow study procedures and complete questionnaires
* Signature of informed consent

Exclusion Criteria:

* Presence of distant metastases at the time of diagnosis
* Previous cancer of the head and neck district
* Second tumor in therapy or follow-up for less than 5 years

Where it's running

• "Regina Elena" National Cancer Institute
  Rome, Italy Recruiting

Study contacts

• Study coordinator: Raul Pellini, Doctor
• Email: raul.pellini@ifo.gov.it
• Phone: 06-52664484

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DARE-HPV: testing a two-dose, two-duration approach to clear persistent hrHPV in women

  This trial tests whether DARE-HPV can clear persistent high-risk HPV in premenopausal women aged 22–50, using two doses and two treatment lengths against a placebo.

  Recruiting at 11 sites Phase 2 Daré Bioscience, Inc. · Mobile, Alabama and 10 other locations · NCT07601074

• Blood exosomal RNA test to rule out prostate cancer spread to bone

  This project will try a blood-based exosomal RNA test to see if it can rule out bone metastasis in people with newly diagnosed, treatment‑naïve prostate cancer scheduled for baseline PSMA PET.

  Recruiting at 9 sites Xijing Hospital · Lanzhou, Gansu and 8 other locations · NCT07553754

• ctDNA analysis on archived plasma to gauge minimal residual disease in epithelial ovarian cancer

  A single-center study will test whether ctDNA from archived and current blood samples can help identify minimal residual disease in epithelial ovarian cancer patients after surgery.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07546578

• Using urinary tumor DNA to guide how long systemic immunotherapy is given for unresectable very‑high‑risk non‑muscle‑invasive bladder cancer.

  This trial will test whether monitoring urinary tumor DNA lets people with unresectable very‑high‑risk non‑muscle‑invasive bladder cancer stop systemic immunotherapy sooner after they have a complete clinical response.

  Recruiting at 3 sites Phase 2 Tianjin Medical University Second Hospital · Tianjin and 2 other locations · NCT07475403

• Intracranial Venous Blood Sampling for Brain Tumor Liquid Biopsy

  This study tests whether taking blood from veins inside the brain can safely and reliably reveal molecular information about high-grade gliomas using a liquid biopsy.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07467109

• Liquid biopsy testing to identify, monitor, and predict recurrence in urothelial carcinoma

  This project tests whether a multi-component liquid biopsy (blood and urine ctDNA, urine tumor DNA, exosomes, and protein biomarkers) can help detect disease, track treatment response, and predict recurrence in people with suspected or confirmed urothelial carcinoma.

  Recruiting Tianjin Medical University Second Hospital · Tianjin · NCT07441499

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.